Welcoming Ben Maurey as a Commercial Advisor

We are excited to welcome Ben Maurey to Reglagene as our commercial-focused advisor on our Advisory Board. Ben comes to Reglagene after 8 years in the oncology space with a wide variety of roles and responsibilities. He started his career off in strategic consulting and eventually ran the Market Strategy Team at Vaniam Group, with his team focusing on early asset and market access strategy. Most recently, Ben ran market insights for early stage assets at Seagen and continued with the company after they were acquired by Pfizer. In addition to his commercial consulting and industry experience Ben has assisted with clinical/medical affairs strategy and was a Venture Partner at The Cancer Fund.